The Journal of Clinical Medicine

Popular Keywords

Pulmonary and Critical Care

Infectious Disease

Pediatrics

Geriatrics and Aging

Palliative Care

Genetics

A Systematic Review of SARS-CoV-2 in Kidney Transplant Recipients

Correspondence to Author: Anurag Kumar Rashmi

Department of Anthropology, University of Delhi, Delhi 110007, India; Email : anurashmi.rana@sgrh.com

Abstract:

Severe acute metabolic process syndrome coronavirus a pair of (SARSCoV-2) has become a worldwide health care crisis. excretory organ transplant (KTx) patients and also the patients with chronic illness|renal disorder|nephropathy|nephrosis|uropathy} ar 2 of the foremost vulnerable populations to the risks of coronavirus disease 2019 (COVID-19). a scientific literature search on PubMed and internet of Science was conducted. we have a tendency to analyzed printed case reports, case series and articles on COVID-19’s clinical presentation, management, outcomes and vaccination among excretory organ transplant recipients. a complete of thirty three studies were enclosed within the study, including 1676 KTx recipients and 108 roll patients infected with COVID-19. These studies according the clinical presentation, management and immunological disorder adjustment among the KTx recipients. The remaining studies centered on alternative aspects, like vaccination and transplantation, throughout the COVID-19 pandemic. Mortality because of COVID-19 was ascertained to be the best for KTx recipients, followed by patients on dialysis, and lowest within the general population. there’s no definitive treatment of COVID-19 nonetheless, and managing transplant patients is enigmatic of this: the treatment is predicated on symptom management. there’s Associate in Nursing pressing want for pointers on managing excretory organ transplant recipients and immunological disorder changes for the course of COVID-19 treatment

Keywords : kidney transplant; SARS-CoV-2; COVID-19; treatment; vaccination; transplant

Introduction: The severe acute metabolism syndrome coronavirus two (SARS-CoV-2), or coronavirus illness nineteen (COVID-19), that originated within the town of metropolis, China, unfold worldwide and become a worldwide pandemic [1,2]. when the primary wave of COVID-19 in March and Apr of 2020, a second wave of COVID-19 evolved in Asian country, the USA, Brazil, Russia, Spain, and France, with the upper rate of infection and unfold [3]. It had infected quite 173 million individuals and caused quite three.7 million deaths worldwide as of eight Gregorian calendar month 2021 [4]. The third international happening of SARS-CoV-2 with the alphabetic character variant (B.1.1.529) has emerged. The potency with that the alphabetic character variant will unfold is high, creating it extraordinarily contagious, additional thus than the first SARS-CoV-2 virus. The transmissibility of the variant is unknown in excretory organ transplant patients. The COVID-19 pandemic has had a putting impact on excretory organ transplantation globally. Patients with chronic nephrosis (CKD) and excretory organ transplant patients ar one among the populations most liable to the risks of COVID-19 [3]. within the u. s. alone, there ar quite [*fr1] 1,000,000 individuals living with finish stage urinary organ illness (ESRD) [5]. More than one hundred and five,234 excretory organ transplants were performed in 2019 everywhere the world. when the happening of COVID-19, all surgeries were stopped as Associate in Nursing early response to the pandemic [6]. A forceful fall within the range of excretory organ transplants was determined, with a fall rate of fifty nine.2% from the one hundred and five,234-plus excretory organ transplants (KTx) in 2019 to forty two,948 KTx in 2020 [7]. Transplant and non-transplant nephrologists’ practices are greatly stricken by the COVID-19 pandemic. Patients on urinary organ replacement medical care have had to go to the hospital for normal check-ups and in emergencies. CKD patients on haemodialysis ar additional prone to the fast unfold of the COVID-19 virus because of regular visits to the haemodialysis ward and waiting areas, exposure throughout transportation, and indirect contact transmission. Transplant analysis Associate in Nursingd surgeries were paused as an early response to the pandemic, however chemical analysis can not be stopped or paused, in contrast to transplants [8]. whereas eightieth of the deceased donor excretory organ transplants within the North American nation were operational, seventy two of living donor transplants were totally close up [9,10]. The revealed reports Associate in Nursingd studies counsel that excretory organ transplant recipients ar at an augmented risk of severe COVID-19 [11], hospital admissions [12], acute excretory organ injury [13] and mortality [12,14]. immunological disorder could be a important a part of the post-transplant regime, that prevents rejection and ensures the longevity of the graft [15–18]. because of the attenuate T cell immunity in transplant recipients, they’re at a high risk of severe microorganism and microorganism infections, and so ar at larger risk of mortality from COVID-19 [19]. One OpenSAFELY project analyzed seventeen million patients for the factors related to COVID-19 deaths. This study according that chemical analysis, surgery and CKD ar 3 of the four comorbidities related to the best mortality risk in COVID-19 cases. the danger related to CKD stages four and five is above that of diabetes [20]. consistent with the world Burden of illness, Associate in Nursing calculable international population of one.7 billion (22%) is at high risk of severe COVID-19 infection. The CKD risk issue related to COVID-19 severity was found in five-hitter of the world population [21]. With the increase of COVID- nineteen cases and infection, augmented stress and anxiety levels also are determined in excretory organ transplant patients, resulting in sleep disturbances and medical specialty disorders, that have an effect on graft perform and cut back the specified high compliance with transplant regimens [22]. The aim of this text was to consistently review the offered revealed literature concerning urinary organ transplant recipients and patients on waiting lists diagnosed with COVIDnineteen everywhere the globe. This paper more deciphers the impact of COVID-19

Materials and ways: Search Strategy A systematic literature search of the articles indexed within the PubMed and net of Science databases was performed to get relevant studies. The search was conducted as of twenty four might 2021 with none language restriction. The terms used for search enclosed “COVID-19”, “SARS-CoV-2”, “kidney transplant” and “chronic urinary organ disease”. Relevant literature reviews and references of enclosed studies were conjointly searched to identify different relevant analyses. This review was conducted in accordance with most well-liked news things for systematic and meta-analysis (PRISMA) tips. the total search strategy is portrayed in Figure one.

Study choice: We enclosed studies and case reports printed till twenty four might 2021 that investigated the impact of COVID-19 on KTx recipients. we tend to thought of all types of printed studies— irregular management trials, non-randomized prospective cohorts, retrospective cohorts, case reports and case series. Inclusion and exclusion criteria were developed to facilitate intensive looking and screening for printed studies and case reports relevant to COVID- nineteen and urinary organ transplantation. Studies together with KTx patients infected with SARS-CoV-2 were enclosed during this review. when the initial screening, the total texts of the articles were reviewed by N.K., R.R. and A.G., that any screened the publications. If the reviewing authors couldn’t reach to a accord for the inclu- sion/exclusion of any specific article, then author M.P.S. was contacted and also the author’s judgement was sought-after

RESULTS: A total of thirty three studies were enclosed during this review. Out of those thirty three studies, twenty four studies rumored 1676 KTx recipients Associate in Nursingd 108 roster patients WHO checked positive for COVID-19 via RT-PCR or with an matter positive SARS-CoV-2 test. Fifteen extra articles were conjointly enclosed during this review that explain the prognosis of COVID-19 infection within the immunized KTx patients and also the effectuality of the vaccines.

Clinical Presentation: The reason for COVID-19 exposure is expounded to community transmission. the typical time between exposure and clinical symptoms is 6–7 days. the foremost common initial symptoms of COVID-19 in KTx recipients enclosed fever [14,19,23–36] cough [14,19,23–35], symptom [14,19,23–28,30–33,35–37] symptom [14,19,23–27,30–32,34,36,37], pain [19,23–26,28–30,32,36] and headache [9,23,25,28,31,34,37]. different rumored symptoms of COVID-19 that weren’t ordinarily determined throughout the primary wave of the pandemic were: loss of style and smell [14,30–33,37], fatigue [19,23,25,37], emesis [19,25,37], abdominal pain [19,23,32] and throat pain [23,37]. From forty second to sixty seven.9% of the KTx COVID-19 patients rumored tormented by acute urinary organ injury (see Table 1) [14,23,31–33,36,38–40]. Caillard et al. determined thirteen.2% acute urinary organ injury (AKI) cases within the non-transplant patient population [31]. Schapiro et al. and Banerjee et al. rumored graft loss in eight.5% [40] and thirty three.3% [38] of the KTx patients because of the COVID-19, severally. Nearly 100% of the KTx recipients underwent nephritic replacement medical aid [14,31,32,40]. Caillard et al. determined the same trend in non-transplant patients conjointly, wherever 100% of the whole admitted non-transplant patients underwent nephritic replacement medical aid (RRT) [31]. The number of KTx patients admitted to ICUs varied greatly from twenty.2% of the patients in an exceedingly study by Oto et al. to fifty two in an exceedingly study by Rinaldi et al. [23,27]. Caillard et al. rumored microorganism infection in nineteen.8% of the KTx patients [31]. Mechanical ventilator support was conjointly provided to the patients, tho’ abundant knowledge aren’t offered on this facet, except within the study conducted by Chavarot et al. and Caillard et al., United Nations agency rumored that twenty ninth of the KTx recipients infected by COVID-19 sickness needed mechanical support [30,31]. The cases of patients being laid low with mucormycosis were rumored round the world and significantly in Asian country [45]. There are a minimum of fourteen,872 cases of mucormycosis in Asian country till the third week of could [46]. The symptoms included: one-sided facial swelling,headache, sinus, black lesions on nasal bridge or in mouth, fever and hurting. it absolutely was rumored to own a deathrate of fifty four [47]. The primary reasons that expedited the condition of mucormycosis in patients with COVID-19 were low O, diabetes, symptom, acidic medium, high iron levels, immunological disorder and prolonged hospitalization. the foremost common location for mu- cormycosis is that the nasal/sinus and orbit, followed by the central systema nervosum, lungs and bones. Mucormycosis was acknowledged to have an effect on patients with kidney-related ailments, even before the pandemic, thanks to their disorder conditions. The rampant use of steroids within the treatment of patients with COVID-19 infection and conditions regarding existing co-morbidities, like polygenic disorder, were a number of the established causes of mucormy- cosis in nonimmunocompromised patients. However, the excretory organ transplant patients square measure still at the next risk of this sickness as a post-COVID-19 complication [45,48–57]

Treatment and medication changes: There is no commonplace or confirmed medication, treatment or medical care for COVID-19. Dif- ferent medicines and coverings square measure administered to the patients principally supported the clinical symptoms they need. anti-inflammatory is employed for COVID-19 patients for each trans- plant and non-transplant classes as rumored within the majority of the studies [14,19,23,27,30– 34,37,42,47]. Azithromycin [19,23,30– 33,37,39,41,47], tocilizumab [14,27,30–33,36,37,42,47], remdesivir [31,32,36,41,42,44], lopinavir/ritonavir [42,44,58– 60], darunavir/cobicistat [24,27,36], favipiravir [23,32,39], oseltamivir [23,31,39], antibiotics [19,23,24,31,32,36,39,41–43] and powerful doses of steroids [27,32,33,36,39] square measure a number of the foremost prescribed medicines (Table 1). Other administered medicines square measure macrolides [23,32], antifungal [31], antiretrovi- ral [47], antiviral drug [47], anakinra [23,42,47], corticosteroids [42,47], glucocorticoids [23] and convalescent plasma medical care [44,61]. endovenous human gamma globulin medical care [11,42] and convalescent plasma medical care [32,39,41,42] have conjointly been rumored as a treatment for moderate to severe COVID-19- infected patients in rumored studies. For the transplant patients stricken by COVID-19, the foremost perplexity is whether or not to change the immunological disorder regimens that square measure prescribed to them for the survival of the graft. within the case of constant with immunological disorder regimens, the chance of the severity of COVID-19 infection will increase, thereby increasing the chance of mortality. many studies and reports printed on-line describe the treatments followed by them in KTx recipients. The treatment is personalized, and no prescription of standardized treatment or medical care is run. several studies and reports rumored that doctors scrutinize every patient and, supported the condition, the choice is formed to discontinue, withdraw, increase or decrease the immunological disorder [14,19,24,26,30,32,36,3 7,42,44,47]. Nair et al. rumored differing kinds of medication changes for every patient that were achieved with a decrease in mycophenolate acid, mycophenolate mofetil, sirolimus or mycophenolate mofetil and tacrolimus along [19]. The intake of Meticorten was conjointly controlled supported the necessity of every patient. Elias et al. delineate the treatment for KTx patients with COVID-19 infection, and also the immunological disorder changes varied from patient to patient looking on the necessity and also the intake of medicines [14]. Kute et al., in an exceedingly multicenter prospective study, delineate the clinical course of 250 KTx patients, wherever they rumored no modification within the steroid indefinite quantity in hour of the patients thanks to COVID-19 positivism, and conjointly that twenty eight.4% of the patients were placed on reduced indefinite quantity or discontinued from the calcineurin matter [32]. Further, for the patients stricken by mucormycosis, antibiotic drug B was given to them and, in severe cases, surgical operation of the affected tissue was the sole offered treatment [49–51].

Mortalities in excretory organ Transplant Recipients thanks to COVID-19 Infection: According to the French and Spanish written record of ERAEDTA, the infection rate of COVID-19 was fourteen cases per one thousand transplants [62]. The Belgian Society of medicine conjointly rumored Associate in Nursing incidence of fourteen cases per one thousand transplants. Patients with a excretory organ transplant appear to be at a bigger risk of severe COVID-19 sickness and mortality [63]. Three studies from ny, the u.s., Akalin et al. and Schapiro et al. rumored a deathrate of half-hour [19], twenty eighth [26] and fifty two [40], severally, among the excretory organ transplant patients thanks to COVID-19. The studies from among the eu region, together with the uk, Spain, Italy and France, the deathrate of KTx patients was half-hour [25], 28% [47], 18% [33], 17% [27], twenty sixth [30] and twenty seventh [14], severally. These knowledge square measure derived from numerous case reports and studies. These printed reports and studies have shown an extraordinarily high deathrate compared to the half of to five within the general population [14,26].

inoculating excretory organ Transplant Recipients: Vaccination has emerged as a vital tool for COVID-19 management. many vaccines for contagious disease, pneumococci, viral hepatitis, herpes zoster and human papillomavirus ar customary and are directed for roster patients yet as excretory organ transplant patients. A majority of the patients respond effectively to those vaccines. in keeping with a global organization’s recommendations on COVID-19, upset patients, together with excretory organ transplant recipients, ar prioritized for vaccination [64,65]. However, this steerage has been discharged with none previous clinical trials as of twenty four could 2021. indicated a positive response of those patients to the template RNA COVID-19 immunizing agent [66]. There ar only a few accessible reports and studies associated with the potency and effects of the COVID-19 vaccines on excretory organ transplant and dialysis patients. The COVID- nineteen vaccines that don’t have the live virus in their composition may be administered to KTx recipients because the live vaccines will cause vaccine-related illness. The vaccines that don’t contain replication-competent SARS-CoV-2 virus don’t have any risks of COVID-19 infection [67–69]. The Centers for illness management discharged pointers for inoculating upset patients, on condition that they are doing not report any contradictions or aversions to any of the immunizing agent parts [70]. to boot, it placed stress on informing and direction the patients concerning the risks, safety and effectiveness of the vaccines, whose edges outweigh the potential risks of the COVID-19 immunizing agent [70,71]. Despite the priority of replication-deficient infectious agent vector-based medicines, Saima et al. reportable no issues for inoculating upset persons [72]. Billany et al. and Attias et al. reportable a sturdy protein response of eightieth seropositivity once the primary and second dose of vaccines, severally, in these patients [73,74]. However, the result of vaccination once the primary and second dose was reportable to be relatively low in patients with CKD, KTx or patients on dialysis [75,76]. there have been no reportable cases of organ rejection or severe allergy thanks to vaccines in transplant recipients. Further, it had been additionally reportable that KTx patients were suggested to attend for 3 months once surgery to become unsusceptible . This stipulated time is one month for different organs that ar transplanted. Patients waiting on a waitlist or undergoing a transplant were additionally radiocontrolled to become unsusceptible and ideally watch for fourteen days once vaccination for the surgery [77]. within the case of acute cellular rejection, protection ought to be avoided till the rejection episode has passed. If the patient has seasoned anti-CD20 antibody treatment, a 6-month interval is suggested between the last rituximab and therefore the SARS-CoV-2 immunizing agent [78].

examination the Impact of COVID-19 among CKD, excretory organ Transplant and General Population Patients: The management of KTx recipients diagnosed with COVID-19 is difficult. A study by Mamode et al. from London, being one amongst the best rife areas for COVID-19, reportable a death rate of half-hour among excretory organ transplant recipients. This coincides with the death rate of roster patients, that was twenty seventh. Among the transplant patients, 20.2% of the patients required ventilator support and fifteen.6% of patients on the roster for a transplant required ventilator support. The symptoms of COVID-19, together with fever, fatigue nausea, symptom and headache, were discovered to be higher among the KTx recipients than in roster patients [25]. In the Rinaldi et al. study cohort, no important distinction was found in 30-day survival among solid operation patients and non-transplant patients. the next rate of infections was discovered in drunkard patients than within the non-transplant patients. some five hundredth of the transplant patients had reportable severe metastasis failure against thirty third of nontransplant patients. The social unit admission among transplant patients was found to be fifty two against nineteen.3% among the non-transplant patients [27]. Chavarot et al. compared the survival rate of excretory organ transplant patients to the nontransplant patients, and located that the survival of transplant patients was kind of like that of non-transplant patients World Health Organization had similar comorbidities, thereby indicating that medication doesn’t create any implications or risk of severe COVID-19 infection [30]. Meester et al. reportable that by the tip of 1st COVID-19 wave, i.e., a pair of March 2020 to twenty five could 2020, 5.31% of the dialysis patients, 1.4% of the KTx recipients and zero.64% of the final population of Flanders, Kingdom of Belgium were full of COVID-19. The mortality rates of COVID-19 were found to be 14 July, 29.6% and 15.3% among KTx recipients, dialysis patients and therefore the general population, severally [63] equally, during a. Moreover, five hundredth of the patients with a transplant had acute excretory organ injury and September 11 of the transplant patients lost graft [40]. Caillard et al. The symptoms among the teams were similar, together with fever, cough, dyspnoea and symptom. However, the acute excretory organ injury rate found in transplant recipients was terribly high at forty five.8%, compared to nontransplant patients, where 13.8% of the patients had AKI. excretory organ replacement medical care was needed in thirteen.2% of the KTx recipients once COVID-19, compared to nine.9% within the non-transplant patients [31].

Transplantation throughout COVID-19 Pandemic: The COVID-19 pandemic has considerably affected transplant surgery and lots of alternative elective surgeries. Early reports from metropolis, China, reported associate enlarged morbidity and mortality in patients undergoing surgery with symptomless COVID-19 infection [79]. Therefore, transplant evaluations associated surgeries were paused as an early response to the pandemic [8]. it’s been recognized for a protracted time that excretory organ transplantation offers a higher prognosis over qualitative analysis [80–82]. However, the danger of COVID-19 infection is unknown and restricted knowledge square measure obtainable. A mixed result’s determined from the printed studies, wherever a risk of the severity and morbidity of COVID-19 has been found among KTx recipients and patients on waiting lists or qualitative analysis [26,27,30,31,40,63]. Ravanan et al. studied the united kingdom register and located that the roll patients square measure a lot of seemingly to become infected and fewer seemingly to die of COVID-19 than KTx recipients [83]. The yank Society of Transplant Surgeons (AST) and also the Transplantation Society developed recommendations for donor and recipient safety [84–86]. It explicit that COVID- 19-recovered people are often evaluated for organ donation and gift when twenty eight days of symptom resolution and when a provision of a negative COVID-19 report. Kanchi et al. reported 2 cases of excretory organ transplant surgeries wherever, within the 1st case, the recipient tested positive, and within the alternative, each donor and recipient tested positive for COVID-19 [87]. when 2–4 weeks of testing negative, the transplant surgery was performed, and each the recipients were reported to be doing well within the follow ups. Further the choice to perform the transplant depends on many factors and sit- uations. It depends upon the unfold of COVID-19 within the space wherever the recipients and donors live, the supply of transplant surgeons, transplant groups and also the medical instrumentality [88]. Various international organizations have fashioned tips for excretory organ transplant throughout the days of COVID-19. it’s suggested for the transplant team and doctors to encourage the recipient to become insusceptible for SARS-CoV-2 a minimum of fourteen days before transplant surgery. it’s suggested that alternative social unit members of the recipients ought to additionally become insusceptible themselves [69]. when transplantation, the most effective time for turning into insusceptible is 3 months post-transplant, providing the recipient doesn’t encounter any case of infection or acute cellular rejection [78]. Even when vaccina- tion, COVID-19- appropriate behaviors ought to be followed by the recipient additionally because the social unit members.

prevalence of COVID-19 among insusceptible excretory organ Transplant Patients: After the primary dose of the SARS-CoV-2 immunogen, solely 11–17% of the patients devel- oped anti-spike antibodies when 20–28 days of vaccination [66,76,89]. Among the doubleinsusceptible KTx recipients, 36–59% had developed antibodies when twenty eight days of vaccina- tion [90–93]. A study by Caillard et al. on the prevalence of coronavirus sickness 2019 in fifty five solid operation patients when 2 doses of mRNAbased COVID-19 immunogen reported that just about twenty seventh of the patients needed atomic number 8 support. 46 patients had re- ceived the BNT162b2 (Pfizer-BioNTech) and 9 have received the mRNA-1273 (Moderna) vaccines. Further, just about St Martin’s Day of the patients were admitted to unit, and 5.5% of the patients died. Out of those fifty five patients, 3 patients were kidney–pancreas transplant recipients, and also the rest were excretory organ recipients [94]. A study from Republic of India reported on four KTx recipients infected with COVID-19. 2 of the patients received one dose and also the alternative 2 received a double dose of Oxford- AstraZeneca (Covishield). The study speculated that the response of the KTx patients to the immunogen was suboptimal, and also the recipients were a lot of susceptible to severe COVID-19, even when vaccination. during this study one in all the patients died when eight days of admission, 2 patients required ventilator support and one patient recovered (shown in Table 2) [95]. Aslam et al. reported on four cases of patients with COVID-19 among solid operation patients, out of that one was a KTx recipient. The patient received the BNT162b2 immunogen and was diagnosed with COVID-19 when seventy two days of the second dose. The symptoms of the patient were moderate, with diarrhoea, and that they had no metabolic process symptoms [96]. Another study by Ali et al. on the event of COVID-19 infection among solid operation patients conferred fourteen cases of transplant patients with ten KTx recipients. Six out of 10 patients had received BNT162b2, 3 received mRNA1273 and one received the Ad26.COV2.S (Janssen/Johnson & Johnson) immunogen for COVID-19. All the patients were alive, aside from 2, United Nations agency were still hospitalized. Four patients conferred severe symptoms, whereas the remainder old delicate and mild–moderate symptoms [97].On the premise of alittle study on twelve solid operation recipients, it absolutely was found that the Ad26.COV2.S immunogen showed a poor body substance response in upset patients, with solely 2 patients reportage the event of antibodies against the spike supermolecule in COVID-19 patients. The study additionally advised that the Janssen immunogen might even lower the body substance immunity in upset patients in distinction to the mRNA-based vaccines [99]. a powerful response to the mRNAbased immunogen was determined among KTx recipients United Nations agency had a history of coronavirus sickness 2019 infection [100–102]. The protein titers in these patients were kind of like the non-immunocompromised patients.

REFERENCES: 1. Lentine, K.L.; Mannon, R.B.; Josephson, M.A. Practicing with Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. Am. J. Kidney Dis. 2021, 77, 777–785. [CrossRef] [PubMed] 2. Ahn, C.; Amer, H.; Anglicheau, D.; Ascher, N.; Baan, C.; Battsetset, G.; Bat-Ireedui, B.; Berney, T.; Betjes, M.; Bichu, S.; et al. Global Transplantation COVID Report March. Transplantation 2020, 104, 1974–1983. [CrossRef] [PubMed] 3. Salvalaggio, P.R.; Ferreira, G.F.; Caliskan, Y.; Vest, L.S.; Schnitzler, M.A.; de Sandes-Freitas, T.V.; Moura, L.R.; Lam, N.N.; Maldonado, R.A.; Loupy, A.; et al. An International survey on living kidney donation and transplant practices during the COVID-19 pandemic. Transpl. Infect. Dis. 2021, 23, e13526. [CrossRef] 4. Centers for Disease Control and Prevention. People with Certain Medical Conditions. Available online: https://www. cdc.gov/ coronavirus/2019-ncov/need-extra-precautions/ people-with-medical-conditions.html (accessed on 24 May 2021). 5. Raja, M.A.; Mendoza, M.A.; Villavicencio, A.; Anjan, S.; Reynolds, J.M.; Kittipibul, V.; Fernandez, A.; Guerra, G.; Camargo, J.F.; Simkins, J.; et al. COVID-19 in solid organ transplant recipients: A systematic review and metaanalysis of current literature. Transplant. Rev. 2021, 35, 100588. [CrossRef] 6. Molnar, M.Z.; Bhalla, A.; Azhar, A.; Tsujita, M.; Talwar, M.; Balaraman, V.; Sodhi, A.; Kadaria, D.; Eason, J.D.; Hayek, S.S.; et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am. J. Transplant. 2020, 20, 3061–3071. [CrossRef] 7. Elias, M.; Pievani, D.; Randoux, C.; Louis, K.; Denis, B.; DeLion, A.; Le Goff, O.; Antoine, C.; Greze, C.; Pillebout, E.; et al. COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. J. Am. Soc. Nephrol. 2020, 31, 2413–2423. [CrossRef] 8. Webster, A.C.; Woodroffe, R.C.; Taylor, R.S.; Chapman, J.R.; Craig, J. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331, 810. [CrossRef] 9. Woodle, E.S.; First, M.R.; Pirsch, J.; Shihab, F.; Gaber, A.O.; Van Veldhuisen, P.; Corticosteroid Withdrawal Study Group. A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, LowDose Corticosteroid Therapy. Ann. Surg. 2008, 248, 564– 577. [CrossRef] [PubMed] 10. Brennan, D.C.; Daller, J.A.; Lake, K.D.; Cibrik, D.; Del Castillo, D. Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation. N. Engl. J. Med. 2006, 355, 1967– 1977. [CrossRef] 11. Matas, A.J.; Kandaswamy, R.; Humar, A.; Payne, W.D.; Dunn, D.L.; Najarian, J.S.; Gruessner, R.W.G.; Gillingham, K.J.; McHugh, L.E.; Sutherland, D.E.R. Long-term Immunosuppression, Without Maintenance Prednisone, After Kidney Transplantation. Ann. Surg. 2004, 240, 510– 517. [CrossRef] [PubMed] 12. Nair, V.; Jandovitz, N.; Hirsch, J.S.; Nair, G.; Abate, M.; Bhaskaran, M.; Grodstein, E.; Berlinrut, I.; Hirschwerk, D.; Cohen, S.L.; et al. COVID-19 in kidney transplant recipients. Am. J. Transplant. 2020, 20, 1819–1825. [CrossRef] [PubMed] 13. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19- related death using OpenSAFELY. Nature 2020, 584, 430– 436. [CrossRef] [PubMed] 14. Clark, A.; Jit, M.; Warren-Gash, C.; Guthrie, B.; Wang, H.H.X.; Mercer, S.W.; Sanderson, C.; McKee, M.; Troeger, C.; Ong, K.L.; et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modelling study. Lancet Glob. Health 2020, 8, e1003–e1017. [CrossRef] 15. Barutcu Atas, D.; Aydin Sunbul, E.; Velioglu, A.; Tuglular, S. The association between perceived stress with sleep quality, insomnia, anxiety and depression in kidney transplant recipients during COVID-19 pandemic. PLoS ONE 2021, 16, e0248117. [CrossRef] 16. Oto, O.A.; Ozturk, S.; Turgutalp, K.; Arici, M.; Alpay, N.; Merhametsiz, O.; Sipahi, S.; Ogutmen, M.B.; Yelken, B.; Altiparmak, M.R.; et al. Predicting the outcome of COVID-19 infection in kidney transplant recipients. BMC Nephrol. 2021, 22, 1–16. [CrossRef] 17. Gandolfini, I.; Delsante, M.; Fiaccadori, E.; Zaza, G.; Manenti, L.; Degli Antoni, A.; Peruzzi, L.; Riella, L.V.; Cravedi, P.; Maggiore, U. COVID-19 in kidney transplant recipients. Am. J. Transplant. 2020, 20, 1941–1943. [CrossRef] 18. Mamode, N.; Ahmed, Z.; Jones, G.; Banga, N.; Motallebzadeh, R.; Tolley, H.; Marks, S.; Stojanovic, J.; Khurram, M.A.; Thurais- ingham, R.; et al. Mortality Rates in Transplant Recipients and Transplantation Candidates in a High-prevalence COVID-19 Environment. Transplantation 2021, 105, 212–215. [CrossRef] 19. Akalin, E.; Azzi, Y.; Bartash, R.; Seethamraju, H.; Parides, M.; Hemmige, V.; Ross, M.; Forest, S.; Goldstein, Y.D.; Ajaimy, M.; et al. Covid-19 and Kidney Transplantation. N. Engl. J. Med. 2020, 382, 2475–2477. [CrossRef] 20. Rinaldi, M.; Bartoletti, M.; Bussini, L.; Pancaldi, L.; Pascale, R.; Comai, G.; Morelli, M.; Ravaioli, M.; Cescon, M.; Cristini, F.; et al. COVID-19 in solid organ transplant recipients: No difference in survival compared to general population. Transpl. Infect. Dis. 2021, 23, e13421. [CrossRef] 21. Abrishami, A.; Samavat, S.; Behnam, B.; Arab-Ahmadi, M.; Nafar, M.; Taheri, M.S. Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients. Eur. Urol. 2020, 78, 281–286. [CrossRef] 22. Zhang, H.; Chen, Y.; Yuan, Q.; Xia, Q.-X.; Zeng, X.-P.; Peng, J.-T.; Liu, J.; Xiao, X.-Y.; Jiang, G.-S.; Xiao, H.-Y.; et al. Identification of Kidney Transplant Recipients with Coronavirus Disease. Eur. Urol. 2020, 77, 742–747. [CrossRef] 23. Chavarot, N.; Gueguen, J.; Bonnet, G.; Jdidou, M.; Trimaille, A.; Burger, C.; Amrouche, L.; Weizman, O.; Pommier, T.; Aubert, O.; et al. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. Am. J. Transplant. 2021, 21, 1285–1294. [CrossRef] 24. Caillard, S.; Chavarot, N.; Francois, H.; Matignon, M.; Greze, C.; Kamar, N.; Gatault, P.; Thaunat, O.; Legris, T.; Frimat, L.; et al. Is COVID-19 infection more severe in kidney transplant recipients? Arab. Archaeol. Epigr. 2021, 21, 1295–1303. [CrossRef] 25. Kute, V.B.; Bhalla, A.K.; Guleria, S.; Ray, D.S.; Bahadur, M.M.; Shingare, A.; Hegde, U.; Gang, S.; Raju, S.; Patel, H.V.; et al. Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study from India. Transplantation 2021, 105, 851–860. [CrossRef] 26. Cucchiari, D.; Guillen, E.; Cofan, F.; Torregrosa, J.; Esforzado, N.; Revuelta, I.; Ventura-Aguiar, P.; Oppenheimer, F.; Bayés, B.; Marcos, M. Ángeles; et al. Taking care of kidney transplant recipients during the COVID-19 pandemic: Experience from a medicalized hotel. Clin. Transplant. 2021, 35, e14132. [CrossRef] 27. Shrivastava, P.; Prashar, R.; Khoury, N.; Patel, A.; Yeddula, S.; Kitajima, T.; Nagai, S.; Samaniego, M. Acute Kidney Injury in a Predominantly African American Cohort of Kidney Transplant Recipients With COVID-19 Infection. Transplantation 2021, 105, 201–205. [CrossRef] 28. Elhadedy, M.A.; Marie, Y.; Halawa, A. COVID-19 in Renal Transplant Recipients: Case Series and a Brief Review of Current Evidence. Nephron 2020, 145, 192–198. [CrossRef] 29. Cravedi, P.; Mothi, S.S.; Azzi, Y.; Haverly, M.; Farouk, S.S.; Pérez-Sáez, M.J.; Redondo-Pachón, M.D.; Murphy, B.; Florman, S.; Cyrino, L.G.; et al. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. Am. J. Transplant. 2020, 20, 3140– 3148. [CrossRef] [PubMed] 30. Giorgakis, E.; Zehtaban, S.P.; Stevens, A.E.; Bhusal, S.; Burdine, L. COVID-19 in solid organ transplant recipients. Transpl. Infect. Dis. 2021, 23, e13419. [CrossRef] 31. Banerjee, D.; Popoola, J.; Shah, S.; Ster, I.C.; Quan, V.; Phanish, M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020, 97, 1076–1082. [CrossRef] 32. Dheir, H.; Sipah, S.; Yaylaci, S.; Cetin, E.S.; Genc, A.B.; First, N.; Koroglu, M.; Muratdagi, G.; Tomak, Y.; Suner, K.O.; et al. Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. Turk. J. Med. Sci. 2021, 51, 428– 434. [CrossRef] 33. Craig-Schapiro, R.; Salinas, T.; Lubetzky, M.; Abel, B.T.; Sultan, S.; Lee, J.R.; Kapur, S.; Aull, M.J.; Dadhania, D.M. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Arab. Archaeol. Epigr. 2021, 21, 1576–1585. [CrossRef] 34. Azzi, Y.; Parides, M.; Alani, O.; Loarte-Campos, P.; Bartash, R.; Forest, S.; Colovai, A.; Ajaimy, M.; Liriano-Ward, L.; Pynadath, C.; et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 2020, 98, 1559–1567. [CrossRef] 35. Coll, E.; Fernández-Ruiz, M.; Sánchez-Álvarez, J.E.; Martínez-Fernández, J.R.; Crespo, M.; Gayoso, J.; BadaBosch, T.; Oppen- heimer, F.; Moreso, F.; López-Oliva, M.O.; et al. COVID-19 in transplant recipients: The Spanish experience. Am. J. Transplant. 2021, 21, 1825–1837. [CrossRef] 36. Fung, M.; Nambiar, A.; Pandey, S.; Aldrich, J.M.; Teraoka, J.; Freise, C.; Roberts, J.; Chandran, S.; Hays, S.R.; Bainbridge, E.; et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl. Infect. Dis.2021, 23. [CrossRef] 37. Naeem, S.; Gohh, R.; Bayliss, G.; Cosgrove, C.; Farmakiotis, D.; Merhi, B.; Morrissey, P.; Osband, A.; Bailey, J.A.; Sweeney, J.; et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl. Infect. Dis. 2021, 23, e13451. [CrossRef] 38. Singh, A.K.; Singh, R.; Joshi, S.R.; Misra, A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 102146. [CrossRef] 39. Raut, A.; Huy, N.T. Rising incidence of mucormycosis in patients with COVID-19: Another challenge for India amidst the second wave? Lancet Respir. Med. 2021, 9, e77. [CrossRef] 40. Centers for Disease Control and Prevention. Fungal Disease. Available online: https://www.cdc.gov/fungal/ diseases/ mucormycosis/index.html (accessed on 24 May 2021). 41. Honavar, S.G.; Sen, M.; Lahane, S.; Lahane, T.P.; Parekh, R. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J. Ophthalmol. 2021, 69, 244–252. [CrossRef] 42. Deb, A.K.; Sarkar, S.; Gokhale, T.; Choudhury, S.S. COVID-19 and orbital mucormycosis. Indian J. Ophthalmol. 2021, 69, 1002–1004. [CrossRef] [PubMed] 43. Mishra, N.; Mutya, V.S.S.; Thomas, A.; Rai, G.; Reddy, B.; Anithakumari, A.M.; Ray, S.; Anand, V.T.; Vishwanth, S.; Hegde, R. A case series of invasive mucormycosis in patients with COVID-19 infection. Int. J. Otorhinolaryngol. Head Neck Surg. 2021, 7, 867–870. [CrossRef] 44. Satish, D.; Joy, D.; Ross, A. Mucormycosis coinfection associated with global COVID-19: A case series from India. Int. J. Otorhinolaryngol. Head Neck Surg. 2021, 7, 815–820. [CrossRef] 45. Moorthy, A.; Gaikwad, R.; Krishna, S.; Hegde, R.; Tripathi, K.K.; Kale, P.G.; Rao, P.S.; Haldipur, D.; Bonanthaya, K. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids— An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. J. Maxillofac. Oral Surg. 2021, 20, 418–425. [CrossRef] [PubMed] 46. Sharma, S.; Grover, M.; Bhargava, S.; Samdani, S.; Kataria, T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J. Laryngol. Otol. 2021, 135, 442–447. [CrossRef] [PubMed] 47. Johnson, A.K.; Ghazarian, Z.; Cendrowski, K.D.; Persichino, J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med. Mycol. Case Rep. 2021, 32, 64–67. [CrossRef] 48. Hanley, B.; Naresh, K.; Roufosse, C.; Nicholson, A.G.; Weir, J.; Cooke, G.S.; Thursz, M.; Manousou, P.; Corbett, R.; Goldin, R.; et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: A post-mortem study. Lancet Microbe 2020, 1, e245–e253. [CrossRef] 49. Kanwar, A.; Jordan, A.; Olewiler, S.; Wehberg, K.; Cortes, M.; Jackson, B. A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19. J. Fungi 2021, 7, 174. [CrossRef] 50. Karimi-Galougahi, M.; Arastou, S.; Haseli, S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int. Forum Allergy Rhinol. 2021, 11, 1029– 1030. [CrossRef] 51. Bajpai, D.; Deb, S.; Bose, S.; Gandhi, C.; Modi, T.; Katyal, A.; Saxena, N.; Patil, A.; Thakare, S.; Pajai, A.E.; et al. Recovery of kidney function after AKI because of COVID-19 in kidney transplant recipients. Transpl. Int. 2021, 34, 1074–1082. [CrossRef] [PubMed] 52. Mahalingasivam, V.; Craik, A.; Tomlinson, L.A.; Ge, L.; Hou, L.; Wang, Q.; Yang, K.; Fogarty, D.G.; Keenan, C. A Systematic Review of COVID-19 and Kidney Transplantation. Kidney Int. Rep. 2021, 6, 24–45. [CrossRef] [PubMed] 53. Keating, B.J.; Mukhtar, E.H.; Elftmann, E.D.; Eweje, F.R.; Gao, H.; Ibrahim, L.I.; Kathawate, R.G.; Lee, A.C.; Li, E.H.; Moore, K.A.; et al. Early detection of SARS-CoV-2 and other infections in solid organ transplant recipients and household members using wearable devices. Transpl. Int.2021, 34, 1019–1031. [CrossRef] 54. ClinicalTrials.gov. Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia. Available online: https: //clinicaltrials.gov/ct2/show/study/ NCT04381858 (accessed on 3 June 2021). 55. Jager, K.J.; Kramer, A.; Chesnaye, N.C.; Couchoud, C.; Sánchez-Álvarez, J.E.; Garneata, L.; Collart, F.; Hemmelder, M.H.; Ambühl, P.; Kerschbaum, J.; et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020, 98, 1540–1548. [CrossRef] 56. Torreggiani, M.; Blanchi, S.; Fois, A.; Fessi, H.; Piccoli, G.B. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: The war is far from being won. Kidney Int. 2021, 99, 1494–1496. [CrossRef] 57. US Government. Centers for Disease Control and Prevention. Influenza. Vaccine Effectiveness—How Well Does the Flu Vaccine Work? Available online: Https://www. Cdc.Gov/flu/vaccines-work/vaccineeffect.Html (accessed on 24 May 2021). 58. European Centre for Disease Control and Prevention. COVID-19 Vaccination and Prioritisation Strategies in the EU/EEA. Available online: https://www.ecdc.europa. eu/en/publications-data/covid-19-vaccination-andprioritisation-strategies-eueea. (accessed on 24 May 2021). 59. Benotmane, I.; Gautier-Vargas, G.; Cognard, N.; Olagne, J.; Heibel, F.; Braun-Parvez, L.; Martzloff, J.; Perrin, P.; Moulin, B.; Fafi-Kremer, S.; et al. Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021, 99, 1487–1489. [CrossRef] 60. Heldman, M.R.; Limaye, A.P. SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know? J. Am. Soc. Nephrol. 2021, 32, 1021–1024. [CrossRef] [PubMed] 61. Stucchi, R.S.; Lopes, M.H.; Kumar, D.; Manuel, O. Vaccine Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation 2018, 102, S72–S80. [CrossRef] 62. Ramesh, V.; Kute, V.B.; Agarwal, S.K.; Prakash, J.; Guleria, S.; Shroff, S.; Sharma, A.; Varma, P.; Prasad, N.; Sahay, M.; et al. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J. Nephrol. 2021, 31, 89–91. [CrossRef] [PubMed] 63. Kronbichler, A.; Anders, H.-J.; Fernandez-Juárez, G.M.; Floege, J.; Goumenos, D.; Segelmark, M.; Tesar, V.; Turkmen, K.; van Kooten, C.; Bruchfeld, A.; et al. Recommendations for the use of COVID-19 vaccines in patients with immunemediated kidney diseases. Nephrol. Dial. Transplant. 2021, 36, 1160–1168. [CrossRef] [PubMed] 64. USA Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines. Avail- able online: https://www.cdc.gov/vaccines/ covid-19/info-by-product/clinical-considerations. html#SARS-CoV-2-infection (accessed on 21 May 2021). 65. Aslam, S.; Goldstein, D.R.; Vos, R.; Gelman, A.E.; Kittleson, M.M.; Wolfe, C.; Danziger-Isakov, L. COVID-19 vaccination in our transplant recipients: The time is now. J. Hear. Lung Transplant. 2021, 40, 169–171. [CrossRef] 66. Billany, R.E.; Selvaskandan, H.; Adenwalla, S.F.; Hull, K.L.; March, D.S.; Burton, J.O.; Bishop, N.C.; Carr, E.J.; Beale, R.; Tang, J.W.; et al. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: A call to arms. Kidney Int. 2021, 99, 1492–1494. [CrossRef] [PubMed] 67. Attias, P.; Sakhi, H.; Rieu, P.; Soorkia, A.; Assayag, D.; Bouhroum, S.; Nizard, P.; El Karoui, K. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021, 99, 1490–1492. [CrossRef] [PubMed] 68. VCU Health. COVID-19 Vaccines and Transplant Patients: Is Vaccine Safe? Available online: https://www.vcuhealth. org/news/ covid-19/covid-19-vaccines-and-transplantpatients-is-it-safe (accessed on 23 May 2021). 69. Benotmane, I.; Gautier-Vargas, G.; Cognard, N.; Olagne, J.; Heibel, F.; Braun-Parvez, L.; Martzloff, J.; Perrin, P.; Moulin, B.; Fafi-Kremer, S.; et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021, 99, 1498–1500. [CrossRef] [PubMed] 70. De Meester, J.; De Bacquer, D.; Naesens, M.; Meijers, B.; Couttenye, M.M.; De Vriese, A.S.; For the NBVN Kidney Registry Group. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. J. Am. Soc. Nephrol. 2021, 32, 385–396. [CrossRef] 71. Negahdaripour, M.; Shafiekhani, M.; Moezzi, S.M.I.; Amiri, S.; Rasekh, S.; Bagheri, A.; Mosaddeghi, P.; Vazin, A. Administration of COVID-19 Vaccines in ImmunocompromisedPatients. Int. Immunopharmacol. 2021, 99, 108021. [CrossRef] [PubMed] 72. Sharma, Y.; Nasr, S.H.; Larsen, C.P.; Kemper, A.; Ormsby, A.H.; Williamson, S.R. COVID-19–Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases. Kidney Med. 2020, 2, 493–497. [CrossRef] 73. Lei, S.; Jiang, F.; Su, W.; Chen, C.; Chen, J.; Mei, W.; Zhan, L.- Y.; Jia, Y.; Zhang, L.; Liu, D.; et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EclinicalMedicine 2020, 21, 100331. [CrossRef] [PubMed] 74. Caillard, S.; Anglicheau, D.; Matignon, M.; Durrbach, A.; Greze, C.; Frimat, L.; Thaunat, O.; Legris, T.; Moal, V.; Westeel, P.F.; et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020, 98, 1549–1558. [CrossRef] [PubMed] 75. Boyarsky, B.J.; Chiang, P.-Y.; Werbel, W.A.; Durand, C.M.; Avery, R.K.; Getsin, S.; Jackson, K.R.; Kernodle, A.B.; Rasmussen, S.E.V.P.; Massie, A.B.; et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Arab. Archaeol. Epigr. 2020, 20, 1809– 1818. [CrossRef] [PubMed] 76. Ravanan, R.; Callaghan, C.J.; Mumford, L.; Ushiro-Lumb, I.; Thorburn, D.; Casey, J.; Friend, P.; Parameshwar, J.; Currie, I.; Burnapp, L.; et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study. Arab.Archaeol. Epigr. 2020, 20, 3008–3018. [CrossRef] [PubMed] 77. Am. Society of Transplantation Surgeon (ASTS). ReEngaging Organ Transplantation in the COVID-19 Era. Available online: https://asts.org/advocacy/covid-19- resources/asts-covid-19-strike-force/re-engaging-organtransplantation-in-the-covid-19-era#.YK4KN6gzbIV (accessed on 21 May 2021). 78. Am. Society of Transplantation (AST). COVID-19 Information. Available online: https://www.myast.org/ covid-19-information# (accessed on 21 May 2021). 79. The Transplantation Society. Transplant Infectious Disease. Available online: https://tts.org/tid-about/tidpresidents-message/ 23-tid/tid-news/657-tid-updateand-guidance-on-2019-novel-coronavirus-2019-ncov-fortransplant-id-clinicians (accessed on 21 May 2021). 80. Kanchi, P.; Sambandam, S.; Siddhan, R.; Soundappan, S.; Vaseekaran, V.P.; Gupta, A. Successful kidney transplantation after COVID-19 infection in two cases. Nefrología 2021, 1–3. [CrossRef] [PubMed] 81. Aster CMI Hospital. Can I Undergo Kidney Transplant during COVID-19? Available online: https://www. asterbangalore.com/ blog/kidney-transplant-duringcovid-kidney-transplant-hospital-in-bangalore-indiaaster-cmi-53 (accessed on 21 May 2021). 82. Boyarsky, B.J.; Werbel, W.A.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. J. Am. Med. Assoc. 2021, 325, 1784. [CrossRef] 83. Haskin, O.; Ashkenazi-Hoffnung, L.; Ziv, N.; Borovitz, Y.; Dagan, A.; Levi, S.; Koren, G.; Hamdani, G.; Levi-Erez, D.; Landau, D.; et al. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. Transplantation 2021, 105, e226–e233. [CrossRef] 84. Boyarsky, B.J.; Werbel, W.A.; Avery, R.K.; Tobian, A.A.R.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. J. Am. Med. Assoc. 2021, 325, 2204–2206. [CrossRef] 85. Marinaki, S.; Adamopoulos, S.; Degiannis, D.; Roussos, S.; Pavlopoulou, I.D.; Hatzakis, A.; Boletis, I.N. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am. J. Transplant. 2021. ahead of print. [CrossRef] 86. Rozen-Zvi, B.; Yahav, D.; Agur, T.; Zingerman, B.; Ben-Zvi, H.; Atamna, A.; Tau, N.; Mashraki, T.; Nesher, E.; Rahamimov, R. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: A prospective cohort study. Clin. Microbiol. Infect. 2021, 27, 1173.e1–1173.e4. [CrossRef] 87. Caillard, S.; Chavarot, N.; Bertrand, D.; Kamar, N.; Thaunat, O.; Moal, V.; Masset, C.; Hazzan, M.; Gatault, P.; Sicard, A.; et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021, 100, 477–479. [CrossRef] 88. Meshram, H.S.; Kute, V.B.; Shah, N.; Chauhan, S.; Navadiya, V.V.; Patel, A.H.; Patel, H.V.; Engineer, D.; Banerjee, S.; Rizvi, J.; et al. COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford–AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India. Transplantation 2021, 105, e100–e103. [CrossRef] 89. Aslam, S.; Adler, E.; Mekeel, K.; Little, S.J. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl. Infect. Dis. 2021, 23, e13705. [CrossRef] 90. Ali, N.M.; Alnazari, N.; Mehta, S.A.; Boyarsky, B.; Avery, R.K.; Segev, D.L.; Montgomery, R.A.; Stewart, Z.A. Development of COVID-19 Infection in Transplant Recipients After SARSCoV-2 Vaccination. Transplantation 2021, 105, e104–e106. [CrossRef] [PubMed] 91. Tau, N.; Yahav, D.; Schneider, S.; Rozen-Zvi, B.; Abu Sneineh, M.; Rahamimov, R. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients. Am. J. Transplant. 2021, 21, 2910–2912. [CrossRef] 92. Boyarsky, B.J.; Chiang, T.P.-Y.; Ou, M.T.; Werbel, W.A.; Massie, A.B.; Segev, D.L.; Garonzik-Wang, J.M. Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients. Transplantation 2021, 105, e82– e83. [CrossRef] [PubMed] 93. Benotmane, I.; -Vargas, G.G.; Gallais, F.; Gantner, P.; Cognard, N.; Olagne, J.; Velay, A.; Heibel, F.; Braun-Parvez, L.; Martzloff, J.; et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. Arab. Archaeol. Epigr. 2021, 21, 3808–3810. [CrossRef] [PubMed] 94. Prendecki, M.; Clarke, C.; Brown, J.; Cox, A.; Gleeson, S.; Guckian, M.; Randell, P.; Pria, A.D.; Lightstone, L.; Xu, X.-N.; et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 2021, 397, 1178–1181. [CrossRef] 95. Goel, R.R.; Apostolidis, S.A.; Painter, M.M.; Mathew, D.; Pattekar, A.; Kuthuru, O.; Gouma, S.; Hicks, P.; Meng, W.; Rosenfeld, A.M.; et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. Sci. Immunol. 2021, 6, 6950. [CrossRef]

Citation:

Anurag Kumar Rashmi. A Systematic Review of SARS-CoV-2 in Kidney Transplant Recipients. The Journal of Clinical Medicine 2024.